7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Bénard J | [From metastatic osteolysis a painful message: beginning to understand with osteoprotegerin? | 2000 | Bull Cancer | pmid:11184451 |
Yamashita T et al. | Retardation in bone resorption after bone marrow ablation in klotho mutant mice. | 2000 | Endocrinology | pmid:10614667 |
Hofbauer LC et al. | The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. | 2000 | J. Bone Miner. Res. | pmid:10646108 |
Kanzawa M et al. | Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. | 2000 | Eur. J. Endocrinol. | pmid:10822231 |
Mukohyama H et al. | The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10777696 |
Atkins GJ et al. | Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. | 2000 | J. Bone Miner. Res. | pmid:10780856 |
Thompson SW and Tonge D | Bone cancer gain without the pain. | 2000 | Nat. Med. | pmid:10802700 |
Honore P et al. | Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. | 2000 | Nat. Med. | pmid:10802707 |
Onyia JE et al. | In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. | 2000 | J. Bone Miner. Res. | pmid:10804015 |
Bateman TA et al. | Osteoprotegerin mitigates tail suspension-induced osteopenia. | 2000 | Bone | pmid:10773583 |
Malyankar UM et al. | Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. | 2000 | J. Biol. Chem. | pmid:10811631 |
Thirunavukkarasu K et al. | The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. | 2000 | J. Biol. Chem. | pmid:10833509 |
Aubin JE and Bonnelye E | Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. | 2000 | Medscape Womens Health | pmid:10792853 |
Fata JE et al. | The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. | 2000 | Cell | pmid:11051546 |
Miyamoto N et al. | Spindle-shaped cells derived from giant-cell tumor of bone support differentiation of blood monocytes to osteoclast-like cells. | 2000 | J. Orthop. Res. | pmid:11052502 |
Kinpara K et al. | Osteoclast differentiation factor in human osteosarcoma cell line. | 2000 | J Immunoassay | pmid:11071251 |
Kaneda T et al. | Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor. | 2000 | J. Immunol. | pmid:11035059 |
Miyamoto T et al. | An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand. | 2000 | Blood | pmid:11110710 |
Proposed standard nomenclature for new tumor necrosis factor members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. | 2000 | Bone | pmid:11113385 | |
Takayanagi H et al. | T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. | 2000 | Nature | pmid:11117749 |
Mancini L et al. | Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin. | 2000 | Biochem. Biophys. Res. Commun. | pmid:11118297 |
Lee ZH et al. | Activation of c-Jun N-terminal kinase and activator protein 1 by receptor activator of nuclear factor kappaB. | 2000 | Mol. Pharmacol. | pmid:11093794 |
Kong YY and Penninger JM | Molecular control of bone remodeling and osteoporosis. | 2000 | Exp. Gerontol. | pmid:11121682 |
Shalhoub V et al. | Characterization of osteoclast precursors in human blood. | 2000 | Br. J. Haematol. | pmid:11122091 |
Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. | 2000 | J. Bone Miner. Res. | pmid:11127193 | |
Sakuma Y et al. | Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. | 2000 | Infect. Immun. | pmid:11083800 |
Riggs BL | The mechanisms of estrogen regulation of bone resorption. | 2000 | J. Clin. Invest. | pmid:11086020 |
Udagawa N et al. | Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. | 2000 | Endocrinology | pmid:10965921 |
Yasuda H | [A new paradigm of osteoclast biology: discovery of OCIF and ODF]. | 2000 | Seikagaku | pmid:10967683 |
Teitelbaum SL | Bone resorption by osteoclasts. | 2000 | Science | pmid:10968780 |
Lacey DL et al. | Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. | 2000 | Am. J. Pathol. | pmid:10934148 |
Quinn JM et al. | Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. | 2000 | J. Bone Miner. Res. | pmid:10934644 |
Min H et al. | Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. | 2000 | J. Exp. Med. | pmid:10952716 |
Shiba H et al. | Effects of ageing on proliferative ability, and the expressions of secreted protein, acidic and rich in cysteine (SPARC) and osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human periodontal ligament cells. | 2000 | Mech. Ageing Dev. | pmid:10958924 |
López FJ | New approaches to the treatment of osteoporosis. | 2000 | Curr Opin Chem Biol | pmid:10959765 |
Nakashima T et al. | Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10973797 |
Itoh K et al. | Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. | 2000 | J. Bone Miner. Res. | pmid:10976996 |
Schinke T and Karsenty G | Vascular calcification--a passive process in need of inhibitors. | 2000 | Nephrol. Dial. Transplant. | pmid:10978374 |
Lorenzo J | Interactions between immune and bone cells: new insights with many remaining questions. | 2000 | J. Clin. Invest. | pmid:10995785 |
Teng YT et al. | Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. | 2000 | J. Clin. Invest. | pmid:10995794 |
Børset M et al. | Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. | 2000 | Blood | pmid:11001907 |
Hofbauer LC and Heufelder AE | Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. | 2000 | J. Clin. Endocrinol. Metab. | pmid:10902778 |
Rani CS and MacDougall M | Dental cells express factors that regulate bone resorption. | 2000 | Mol. Cell Biol. Res. Commun. | pmid:10860862 |
Huang L et al. | Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. | 2000 | Am. J. Pathol. | pmid:10702390 |
Capparelli C et al. | Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. | 2000 | Cancer Res. | pmid:10706080 |
Makhluf HA et al. | Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10679262 |
Merewether LA et al. | Development of disulfide peptide mapping and determination of disulfide structure of recombinant human osteoprotegerin chimera produced in Escherichia coli. | 2000 | Arch. Biochem. Biophys. | pmid:10683254 |
Ross FP | RANKing the importance of measles virus in Paget's disease. | 2000 | J. Clin. Invest. | pmid:10712423 |
Tricot G | New insights into role of microenvironment in multiple myeloma. | 2000 | Lancet | pmid:10675068 |
Takayanagi H et al. | Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. | 2000 | Arthritis Rheum. | pmid:10693864 |
Itonaga I et al. | Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages. | 2000 | Ann. Rheum. Dis. | pmid:10627423 |
Chikatsu N et al. | Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10631114 |
Takami M et al. | Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. | 2000 | Endocrinology | pmid:11108286 |
Gori F et al. | The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. | 2000 | Endocrinology | pmid:11108292 |
Clohisy DR et al. | Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. | 2000 | J. Orthop. Res. | pmid:11192258 |
Aubin JE and Bonnelye E | Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. | 2000 | Osteoporos Int | pmid:11193242 |
Wise GE et al. | Osteoprotegerin and osteoclast differentiation factor in tooth eruption. | 2000 | J. Dent. Res. | pmid:11201042 |
Kotake S et al. | [Molecular mechanism of bone metabolism]. | 2000 | Nippon Naika Gakkai Zasshi | pmid:11215116 |
Kanematsu M et al. | [Clinostat rotation culture modulates gene expression of osteoclastogenesis-regulating factors via a cyclic-AMP dependent mechanism]. | 2000 | Biol. Sci. Space | pmid:12561872 |
Kikuchi T et al. | Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. | 2001 | J. Immunol. | pmid:11207318 |
O'Brien EA et al. | Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. | 2001 | Bone | pmid:11182380 |
Zhang YH et al. | Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. | 2001 | J. Biol. Chem. | pmid:11032840 |
Goltzman D | Osteolysis and cancer. | 2001 | J. Clin. Invest. | pmid:11375409 |
Zhang J et al. | Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. | 2001 | J. Clin. Invest. | pmid:11375413 |
Kostenuik PJ and Shalhoub V | Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. | 2001 | Curr. Pharm. Des. | pmid:11375772 |
Lories RJ and Luyten FP | Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets. | 2001 | Clin. Rheumatol. | pmid:11254237 |
Wan M et al. | Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegrin gene expression. | 2001 | J. Biol. Chem. | pmid:11139569 |
Browner WS et al. | Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. | 2001 | J. Clin. Endocrinol. Metab. | pmid:11158021 |
Hofbauer LC and Heufelder AE | [Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases]. | 2001 | Dtsch. Med. Wochenschr. | pmid:11233883 |
Bolon B et al. | Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. | 2001 | Mol. Ther. | pmid:11237676 |
Sasaki N et al. | Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. | 2001 | Nephrol. Dial. Transplant. | pmid:11239019 |
Takeuchi T et al. | Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. | 2001 | Biochem. Pharmacol. | pmid:11239501 |
Mori K et al. | Cross-talk between RANKL and FRP-1/CD98 Systems: RANKL-mediated osteoclastogenesis is suppressed by an inhibitory anti-CD98 heavy chain mAb and CD98-mediated osteoclastogenesis is suppressed by osteoclastogenesis inhibitory factor. | 2001 | Cell. Immunol. | pmid:11243701 |
Hofbauer LC et al. | Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11162519 |
Brändström H et al. | Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11162596 |
Wuyts W et al. | Evaluation of the role of RANK and OPG genes in Paget's disease of bone. | 2001 | Bone | pmid:11165949 |
Michigami T et al. | Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. | 2001 | Cancer Res. | pmid:11245477 |
Feuerherm AJ et al. | Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. | 2001 | Scand. J. Rheumatol. | pmid:11578019 |
Sakai E et al. | Characterization of phagosomal subpopulations along endocytic routes in osteoclasts and macrophages. | 2001 | J. Biochem. | pmid:11726283 |
Quinn JM et al. | Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. | 2001 | J. Bone Miner. Res. | pmid:11585342 |
Choi SJ et al. | Osteoclast inhibitory peptide 2 inhibits osteoclast formation via its C-terminal fragment. | 2001 | J. Bone Miner. Res. | pmid:11585344 |
Miyamoto T et al. | Bifurcation of osteoclasts and dendritic cells from common progenitors. | 2001 | Blood | pmid:11588053 |
Pearse RN et al. | Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11562486 |
Kostenuik PJ et al. | OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. | 2001 | Endocrinology | pmid:11564687 |
Marco-Mingot M et al. | Lack of mutations in the RANK gene in Spanish patients with Paget disease of bone. | 2001 | Clin. Genet. | pmid:11531977 |
Raffai RL et al. | Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11553788 |
Hocking LJ et al. | Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. | 2001 | Am. J. Hum. Genet. | pmid:11555792 |
Hofbauer LC et al. | Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. | 2001 | Cancer | pmid:11505389 |
Hofbauer LC and Heufelder AE | Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. | 2001 | J. Mol. Med. | pmid:11485016 |
Wise GE et al. | Effects of dexamethasone on tooth eruption in rats: differences in incisor and molar eruption. | 2001 | Clin Anat | pmid:11301468 |
Atkins GJ et al. | Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. | 2001 | Bone | pmid:11336917 |
Komine M et al. | Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. | 2001 | Bone | pmid:11344046 |
Chen D et al. | ELISA methodology for detection of modified osteoprotegerin in clinical studies. | 2001 | Clin. Chem. | pmid:11274028 |
Collin-Osdoby P et al. | Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. | 2001 | J. Biol. Chem. | pmid:11274143 |
Brown JM et al. | Osteoprotegerin and rank ligand expression in prostate cancer. | 2001 | Urology | pmid:11306358 |
Fukagawa M et al. | [PTH and bone metabolism in chronic dialysis patients]. | 2001 | Rinsho Byori | pmid:11307321 |
Horowitz MC et al. | Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. | 2001 | Cytokine Growth Factor Rev. | pmid:11312114 |
Lin DL et al. | Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. | 2001 | Prostate | pmid:11351351 |
Sparks AB et al. | Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. | 2001 | Calcif. Tissue Int. | pmid:11351498 |
Disthabanchong S and González EA | Regulation of bone cell development and function: implication for renal osteodystrophy. | 2001 | J. Investig. Med. | pmid:11352181 |